Royalty Report: Drugs, Cancer, Proteins – Collection: 243462

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Proteins
  • Antibody
  • Cell Line

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 243462

License Grant
Licensor is granting the Danish Licensee access and rights to Licensors data, intellectual property, and other information generated subsequent to August 21, 2001 that relates to the research and development of IL-21 Protein, pursuant to the terms of this Agreement.
License Property
IL-21 Program means all research, preclinical, process development and manufacturing activities that are necessary or desirable for Licensors filing of an IND (Investigational New Drug) with the US FDA for the IL-21 Protein and that take place between January 1, 2003 and Licensors filing of such IND (or such earlier date that the IL-21 Program is terminated. The key activities for the IL-21 Program established by Licensor are summarized.  Promptly after execution and delivery of this Agreement, the Joint Project Team will create a detailed joint work plan, approved by the Joint Steering Committee, containing activities with agreed deliverables, budget, and time lines up to the filing of such IND, that may be amended from time to time by mutual agreement in writing between the parties.

IL-21 Program Inventions means any invention or discovery, whether or not patentable, conceived or reduced to practice by either party or its Affiliates, alone or jointly with others including NN or ZGI, in the course of and during the IL-21 Program that relate to, and arise from work related to, the IL-21 Protein, or the product based on the IL-21 Protein.

IL-21 Program Patent Rights means all patents (including, without limitations, all substitutions, extensions, registrations, confirmations, reissues, reexaminations, renewals, supplementary protection certificates and the like) and patent applications (including, without limitations, any continuations, continuations in part or divisions and any provisional applications) that (a) claim an IL-21 Program Invention, (b) have a date of conception of the invention on or after January 1, 2003 and prior to completion of the IL-21 Program and (c) are owned or controlled by a party or its Affiliates.  Amending the definition of IL-21 Related Patents (a) therein, and  including a new supplement the patents and patent applications as IL-21 Related Patents, to incorporate patent and patent applications with a date of conception of the invention prior to January 1, 2003 owned or controlled by Licensor that claim at least one IL-21 Embodiment, or claim a method of making, manufacture or using at least one IL-21 Embodiment, or claim a process or formulation including mixtures comprising at least one IL-21 Embodiment.

Joint IL-21 Program Patent Rights means all IL-21 Program Patent Rights arising or resulting from inventive work by one or more employees from both parties (or their Affiliates), as to which the employees would be inventors under the patent laws of the United States.  The parties have equal, undivided ownership interests in Joint IL-21 Program Patent Rights.

IL-21 is a protein belonging to a family of cytokines that modify the function of cells in the immune system. IL-21 shares both structural and genetic sequence similarity with interleukin-2 (IL-2), a cytokine approved as a therapy for malignant melanoma and renal cell carcinoma. Licensor has shown that IL-21 regulates the proliferation and functional activity of several populations of immune cells, including cytotoxic T cells (CTL) and natural killer (NK) cells, both of which are thought to be critical in eliminating malignant or virally infected cells from the body. Preclinical studies have indicated that IL-21 is an effective therapy in a number of animal models of cancer.

Field of Use
IL-21 is a protein with potential applications for the treatment of cancer, which Licensor is developing in North America and which Licensor has licensed to Licensee for development in the rest of the world.

IPSCIO Record ID: 319209

License Grant
The Swiss Licensor hereby grants to the German Licensee, and the Licensee accepts, in relation only to the Product, a non exclusive license to use the Intellectual Property, the Licensed Know-How, the Licensed Patents and/or the Protein Free System to develop, have developed, to manufacture, have manufactured, to supply, have supplied, to import, have imported, to use, have used, and to sell and have sold, the Product in the Territory for the Approved Purpose only.
License Property
U. S. 6,593,140 – Animal cell culture

Licensed Patents means patents and patent applications, divisions, continuations, continuation-in-part applications, divisionals, extensions, substitutions, renewals, confirmations, supplementary protection certificates and reissues, throughout the world owned or Controlled by the Licensor and used in the development and/or manufacture of the Product.  Licensed Patents shall also include, but not be limited to patents and patent applications that cover the New General Applications Intellectual Property, as defined in the Development Agreement, as well as patents and patent applications comprised in the Improvements.  In the event the Licensee exercises its option under Clause 14 of the Development Agreement also for a technology transfer and license of the Protein-Free System, Licensed Patents shall also include the Protein-Free Patents.  Short particulars of the Licensed Patents as of the effective date of the Development Agreement are set out hereto.

Product means Licensees single-chain bispecific anti-CD19 antibody (CD19 BiTE®) also known as Blinatumomab or MT103, and any variant of MT103, including covalent modifications and sequence modifications of MT103.

Protein-Free System means Licensors chemically defined, animal component free system of media and feeds consisting of the Protein-Free Feeds, Protein-Free Media, Protein-Free Base Powders, Protein-Free Know-How, Protein-Free Patents and the Supplements used either in combination or individually, as it is used in the development and/or manufacture of the Product and owned or Controlled by Licensor.

Protein-Free Feeds means the concentrated nutrient solutions used in order to maintain the growth and productivity of mammalian cells.

Protein-Free Media means the solution of nutrients used in mammalian cell culture.

Protein-Free Base Powders mean the powders.

Protein-Free Know-How means any information specifically relating to the Protein-Free Feeds, Protein-Free Media, Protein-Free Base Powders or the Supplements.

Protein-Free Patents means any patents and applications covering the Protein-Free Feeds, Protein-Free Media, Protein-Free Base Powders, or the Supplements.

Supplements means the supplement solutions.

Intellectual Property means all intellectual property rights, including (without limitation) patents, patent applications, divisions, continuations, continuation-in-part applications, divisionals, substitutions, confirmations, supplementary protection certificates, reissues, utility models, trademarks, database rights and copyrights and all inventions, know-how, trade secrets, techniques and confidential information and other proprietary knowledge and information which may subsist anywhere in the world, in each case for their full term, and together with any renewals or extensions.

BiTE(R) antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. Typically, antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. BiTE antibodies have been shown to bind T cells to tumor cells, ultimately inducing a self-destruction process in the tumor cells referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations. Through the killing process, T cells start to proliferate, which leads to an increased number of T cells at the site of attack.

Field of Use
Blinatumomab is a BiTE antibody for the treatment of various hematologic cancers. Blinatomumab has achieved the primary endpoint in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and has shown significant clinical activity in an ongoing phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL).

The field of use is for the treatment of cancer by activating the T cells of a patient’s immune system to eliminate cancer cells. T cells are considered the most powerful “killer cells” of the human immune system. Blinatumomab targets the human protein molecule CD19, which is expressed on the surface of tumor cells of certain cancers.

Licensee is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer.

IPSCIO Record ID: 294274

License Grant
The parties collaborated to develop a long-acting Factor VII compound and amended the Original Agreement to incorporate all of the Amendments into one document.

Licensor hereby grants, and agrees to grant, to Swiss Licensee an exclusive (even as to Licensor), royalty-bearing license under the Licensor Intellectual Property in the Field of Use during the Term, (i) to conduct research, sample, develop (including clinical development), manufacture, make, use, market, promote, sell, offer for sale, have sold, distribute, import and export New Products in the Territory, and (ii) to use the Reagents in the Territory solely for the purpose of making New Products. Such license does not permit Licensee (x) to practice or use the Licensor Intellectual Property outside the Field of Use or (y) to sublicense any of its rights without the prior written approval of Licensor.

Licensor hereby grants, and agrees to grant, to Licensee a worldwide, exclusive (even as to Licensor), perpetual, irrevocable, and royalty-bearing (subject only to the payment of royalties in accordance with this agreement) license, with the right to sublicense, to any Carved Factor VII Claims that do not constitute Licensee Improvements for any and all purposes. In addition to the foregoing, Licensor hereby grants, and agrees to grant, to Licensee a worldwide, exclusive (even as to Licensor), perpetual, irrevocable, and royalty-free license, with the right to sublicense, to any Carved Factor VII Claims that constitute Licensee Improvements for any and all purposes.

License Property
New Product shall mean the following (a) any of the Licensee Materials modified using either (i) the Licensor Technology, (ii) any Licensor Improvements, or (iii) any combination of all or some of (i) and (ii) above, and (b) any Licensee Materials covered by any Carved Factor VII Claims (except to the extent such claims constitute Licensee Improvements) .

Potential Carved Factor VII Claims shall mean any composition-of-matter claims and any method of treatment claims that are supported by Patent Rights Controlled by Licensor that (i) do or could explicitly and solely recite and claim Licensee Materials, or (ii) any Licensee Improvements made or reduced to practice by Licensor.

Licensor Technology means the Licensor Patents and any Know-How Controlled by Licensor relating to methods and processes for the glycosylation design and remodeling of proteins, peptides and antibodies, including, without limitation, its GlycoAdvance®, GlycoPEGylation™ and GlycoConjugation™ technologies, and other carbohydrate dynthesis processes, and all Know-How resulting from work conducted by Licensor during the Term.

Licensor Patents means (a) all Patent Rights relating to methods and processes for glycosylation design and remodeling of proteins, peptides and antibodies that are Controlled by Licensor, including, but not limited to (i) the Patent Rights listed, (ii) the Patent Rights developed by Licensor in the conduct of the Work Plan during the Term of this Agreement, and (iii) any later acquired Patent Rights Controlled by Licensor and used to develop any New Product, and (b) all Patent Rights Controlled by Licensor that would be infringed by the research, development (including clinical development), manufacture, making, use, marketing, promotion, sale, offer for sale, distribution, import and export of New Products in the Territory.
US Patent #6,800,468 – UDP-galactose .beta.-N-acetyl-glucosamine .beta.1,3galactosyltransferases, .beta.3Gal-T5
US Patent #6,995,004 – UDP-N-ACETYLGLUCOSAMINE GALACTOSE-.beta. 1,3-N-ACETYLGALACTOSAMINE-.alpha.-R / N-ACETYLGLUCOSAMINE-.beta. 1,3,-N-ACETYLGALACTOSAMINE-.alpha.-R (GLCNAC TO GALNAC) .beta.1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2/4GNT
US Patent #6,635,461 – UDP-N-acetylglucosamine galactose-.beta.1, 3-N-acetylgalactosamine-.alpha.-R/(GlcNAc to GalNAc) .beta.1,6-N-acetylglucosaminyltransferase, C2GnT3

Licensor Improvements means any and all Improvements relating to the Licensor Technology made, conceived, or reduced to practice by (i) either Licensor or Licensee or both in the conduct of the Work Plan under this Agreement, (ii) either Licensor or Licensee or both under this Agreement, (iii) Licensee in the practice of any Licensor Technology under the licenses granted to Licensee in this agreement, or (iv) Licensee in the conduct of any activity using any Ownership Rights assigned to Licensee pursuant to this Agreement, in each case of (i), (ii), (iii) or (iv), other than the Licensee Materials, the Licensee Materials modified using the Licensor Technology and New Product. Specifically excluded from Licensor Improvements are (1) formulations, combinations and methods of treatment to the extent relating to Licensee Materials, the Licensee Materials modified using the Licensor Technology and New Products and (2) analytical techniques and purification methods invented, developed or reduced to practice solely by Licensee that did not originate from or are not derived from Licensor (collectively, the Techniques).

Licensor Intellectual Property means Licensor Technology and the Licensor Improvements.

Patent Rights shall mean individually and collectively any and all patents and/or patent applications and provisional applications, all inventions disclosed therein, and any and all continuations, continuations-in-part, continued prosecution applications, divisions, renewals, patents of addition, reissues, confirmations, registrations, revalidations, revisions and re-examinations thereof, utility models, petty patents, design registrations and any and all patents issuing therefrom and any and all foreign counterparts thereof and extensions of any of the foregoing including without limitation extensions under the U.S. Patent Term Restoration Act, extensions under the Japanese Patent Law, and Supplementary Protection Certificates (SPCs) according to Counsel Regulation (EEC) No. 1768/92 and similar extensions for other patents under any applicable law in any country of the world. Licensee hereby grants to Licensor, for the term of the Work Plan, a non-exclusive, royalty free, license under the Licensee Technology to use such Licensee Technology for the sole purpose of carrying out its obligations under the Work Plan. Licensee shall retain at all times all of its rights, title and interest to the Licensee Technology.

Licensor Exclusive Compounds shall mean any and all forms of erythropoietin and granulocyte colony stimulating factor including, but not limited to, with respect to either of the foregoing full length proteins, truncated proteins, fusion proteins, analogs, mutants, splice variants, and conjugates with other molecular entities such as proteins, peptides, organic or inorganic substances.

Field of Use
Licensor's technology is to develop and commercialize next-generation versions of Factors VIIa, VIII and IX.

Factor VIIa is used in the treatment of bleeding episodes and for the prevention of bleeding during surgery or invasive procedures in patients with congenital hemophilia with inhibitors to coagulation factors VIII or IX.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.